Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker    Newsletter   Tax Corner NRI Centre Forums E-Mail Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Bhel 240.75 5.04
Hindalco 170.10 1.10
Ong Corp 435.15 1.73
Ntpc Ltd 137.70 1.18
Tata Pow 86.90 1.97
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Glenmark Pharmaceutical Limited
Glenmark Pharmaceutical Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:532296NSE:GLENMARKBloomberg:GNP@INReuters:GLEN.BO
Market Lot: 1Face Value: 1ISIN Demat: INE935A01035
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
20-AUG-14 Glenmark Pharmaceutical (Glenmark), a manufacturer of generic formulation products and API, announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 dispecific antibody. GBR 1302 was discovered and developed by the Glenmark Biologics Research Centre located in La Chaux-de-Fonds, Switzerland. 15-JUL-14 Glenmark Generics, USA, the subsidiary of Glenmark Generics, has...   More..
Business Profile Future Plans
One To One
Recent news
Latest News
Glenmark Pharma discovers GBR 1302 oncology molecule  -IRIS 20-Aug-14
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Mar-2014 (12)31-Mar-2013 (12)31-Mar-2012 (12)
Net sales 22735.5719352.8815468.16
Other Income671.341162.45551.04
Total Income23406.9120515.3316019.20
Cost of goods sold18049.3616168.6012536.90
OPBDIT5357.554346.733482.30
PAT4338.243861.072652.99
Gross Block---
Equity capital271.22270.85270.53
EPS (Rs.)16.0114.269.81
DPS (Rs.)---
BV (Rs.)---
P/E range (x)28.97 - 38.2321.11 - 38.6326.78 - 35.80
Debt / Equity (x)---
Operating margin (% of OI)22.921.221.7
Net margin (% of OI)18.518.816.6
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
B/ 2, Mahalaxmi Chambers
22, Bhulabhai Desai Road
Mumbai
Maharashtra-400 026
PHONE
- - -
FAX
- - -
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Trade On-line | Wealth Tracker | Newsletters | Tax Corner | NRI Centre | Forums | E-mail | Chat | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer